Glaxo to Pursue Work of Biogen Lab

ZURICH—Officials at Glaxo, the British pharmaceutical giant that has agreed to purchase the Geneva research laboratory of Biogen N.Y., have promised that the facility will retain a degree of autonomy as an intemational center of excellence in biotechnology. John Barr, a spokesman for Glaxo, said that the laboratory will be integrated into the company’s general research program and renamed the Glaxo Institute for Molecular Biology. The new director of research will be Allan Will

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ZURICH—Officials at Glaxo, the British pharmaceutical giant that has agreed to purchase the Geneva research laboratory of Biogen N.Y., have promised that the facility will retain a degree of autonomy as an intemational center of excellence in biotechnology.

John Barr, a spokesman for Glaxo, said that the laboratory will be integrated into the company’s general research program and renamed the Glaxo Institute for Molecular Biology. The new director of research will be Allan Williamson, who previously headed Glaxo’s mammalian research interests in the United Kingdom. Glaxo will assume responsibility for work on the immune modulators interleukin-2 and granulocyte-macrophage colony stimulating factor, both now in clinical trials.

The July 28 announcement of the sale of the Geneva facility was totally unexpected. Officials of Biogen, based in Cambridge, Mass., had been holding discussions for several months with a number of firms in an attempt to stanch losses that topped $20 million last ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Marc Nicholls

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide